Episode Details

Intellia Therapeutics is soaring with an 83% stock surge this year, fueled by promising early data on its lead drug lonvo-z, which slashes painful swelling attacks in rare patients—many even attack-free after one dose. Analysts eye another 57% upside, but the ride isn’t smooth: nex-z, in partnership with Regeneron, faces past safety hurdles including a trial pause over liver damage, and gene-editing therapies risk steep insurance and access challenges. While lonvo-z’s gains may already be priced in, nex-z’s fate could trigger wild swings—making this a high-risk, high-reward play for bold investors only.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/fb3b8bcfe2362859